# Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
Canonical URL: https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-key-opinion-leader-webinar-hosted-by-alliance-global-pa-41d26f60
Ticker: RVPH
Company: Reviva Pharmaceuticals
Source: Reviva Pharmaceuticals
Published: 2025-10-07 20:08 EST
## Summary

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...

## Article Body
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.

The webinar will feature an in-depth Fireside Chat with RVPH CEO Laxminarayan Bhat, PhD, and KOLs including Dr. Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research) and Dr. Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). The unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia and the phase 3 clinical data of Reviva’s lead drug candidate brilaroxazine for schizophrenia will be discussed. The conversation will be moderated by A.G.P./Alliance Global Partners' James Molloy.

To register for the event, please click here . A replay of the webinar will be accessible in the investors section of Reviva’s website following the event.

About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact: Reviva Pharmaceuticals Holdings, Inc. Laxminarayan Bhat, PhD www.revivapharma.com

Investor Relations Contact: LifeSci Advisors, LLC PJ Kelleher pkelleher@lifesciadvisors.com
## Recent Company News
- 2026-05-18 12:00 EST — [Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase](https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-fireside-chat-at-a-g-p-s-annual-healthcare-company-show-840282ca) — Source: Reviva Pharmaceuticals
- 2026-05-13 20:35 EST — [Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/RVPH/reviva-reports-first-quarter-2026-financial-results-and-recent-business-highligh-95d102d4) — Source: Reviva Pharmaceuticals
- 2026-04-23 12:00 EST — [Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications](https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazine-s-pote-52ff9238) — Source: Reviva Pharmaceuticals
- 2026-04-15 12:00 EST — [Reviva Announces Letter to Shareholders](https://biopharmsignal.com/news/RVPH/reviva-announces-letter-to-shareholders-a6780413) — Source: Reviva Pharmaceuticals
- 2026-03-30 10:05 EST — [Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/RVPH/reviva-reports-full-year-2025-financial-results-and-recent-business-highlights-e3bf9f95) — Source: Reviva Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)